CEO Ulrika Kolsrud attributed the sales growth to higher volumes in the Health & Medical, Personal Care, and Professional Hygiene segments. Despite these gains, the Consumer Tissue division struggled, facing lower volumes and price pressures that the company has yet to offset through its current pricing strategy. The overall EBITA margin slipped to 13.4%, down from 13.7% in the same period last year.
To navigate the volatile external environment, Essity is leaning into operational efficiency and digital transformation. The company has integrated AI-driven solutions across its value chain, including a new procurement tool designed to optimize data quality and reduce development lead times. Simultaneously, management continues to execute a SEK 3 billion share buyback program initiated in May, signaling confidence in the firm’s long-term value creation. Looking ahead, leadership expects the benefits of a recent organizational restructuring to materialize in the second half of the year, provided that cost-saving programs successfully mitigate ongoing transportation and raw material inflation.
Comments (0)
No comments yet. Be the first!